百花医药 (600721.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

71.2x

Market Cap

CNY 5.46B

MomentumView details →

1D Return

+7.09%

YTD Return

−2.45%

RSI (14)

47.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

71.2x

Market Cap

CNY 5.46B

RSI (14)

47.8

MomentumView details →

1D Return

+7.09%

YTD Return

−2.45%

ProfitabilityView details →

Gross Margin

44.41%

Net Margin

7.42%

EBITDA Margin

17.81%

ROE (TTM)

3.29%

ROA (TTM)

2.43%

Asset Turnover

0.33x

GrowthView details →

Revenue YoY

−8.48%

EPS YoY

−36.15%

FCF YoY

−8.87%

Revenue CAGR 3Y

+3.54%

EPS CAGR 3Y

+75.97%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

2.36x

Quick Ratio

2.24x

Div Yield

0.34%

Div Rate

CNY 0.04

Div Growth 1Y

−29.72%

Financials snapshotView financials →

Revenue (TTM)

358.59M

Net Income (TTM)

26.61M

Op. CF (TTM)

38.05M

Latest newsMore news →

Baihua Pharmaceutical announced its 2026 first-half results: revenue of 157 million yuan, down 22.13% year-on-year; net profit attributable to shareholders of 14.76 million yuan, down 42.08% year-on-year.11d ago

Similar companies

The Cheesecake Factory IncorporatedCAKE Auntea Jenny (Shanghai) Industrial Co., Ltd.02589.HK Jersey Mike's Subs Inc.JMKE Dutch Bros Inc.BROS Super Hi International Holding Ltd.09658.HK CAVA Group, Inc.CAVA Find similar companies →

Latest newsMore news →

Baihua Pharmaceutical announced its 2026 first-half results: revenue of 157 million yuan, down 22.13% year-on-year; net profit attributable to shareholders of 14.76 million yuan, down 42.08% year-on-year.11d ago